{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:25:41Z","timestamp":1787725541811,"version":"build-2784847793"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The frequency of low-level viremia (LLV) may vary across China. This study aims to analyze the epidemiological characteristics and related factors of LLV among HIV\/AIDS patients in Guizhou Province from 2016 to 2022, and further analyze the impact of LLV on virological failure (VF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Research design and methods<\/jats:title><jats:p>In this retrospective cohort study, we analyzed people living with HIV\/AIDS whose demographic data, CD4<jats:sup>+<\/jats:sup> T lymphocyte count, and viral load. LLV was defined as at least one VL measurement between 50 and 999 copies\/mL after ART. Viral suppression refers to the maintenance of a VL\u202f&amp;lt;\u202f50 copies\/mL after undergoing ART. VF was defined as a VL\u202f\u2265\u202f1,000 copies\/mL after ART. To examine and compare the incidence of LLV at different levels, this study divided LLV into three groups based on previous research definitions: low-level LLV (LLLV) ranging from 50 to 199 copies\/mL, medium-level LLV (MLLV) ranging from 200 to 399 copies\/mL, and high-level LLV (HLLV) ranging from 400 to 999 copies\/mL. LLV occurrence frequency was divided into two groups: intermittent LLV (iLLV) was defined as one independent LLV with both the previous and the subsequent viral load below the lower limit of detection. Persistent LLV (pLLV) was defined as at least two consecutive episodes of LLV. We divided the people living with HIV\/AIDS into two sub-cohorts based on whether they experienced LLV. Non-LLV was defined as never having experienced LLV. We compared the occurrence of LLV at different levels and frequencies, as well as the risk of virological failure (VF), using the Chi-square test. Non-conditional binary logistic regression analysis was used to identify factors influencing LLV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 28,613 cases of infection were analyzed, with 33.72% (9,649\/28,613) exhibiting LLV. The LLV proportion rates were 20.69, 6.50, and 6.48% in the low-level LLV (LLLV) (50\u2013199 copies\/mL), medium-level LLV (MLLV) (200\u2013399 copies\/mL), and high-level LLV (HLLV) (400\u2013999 copies\/mL) groups, respectively. The intermittent LLV (iLLV) and persistent LLV (pLLV) groups had LLV rates of 28.65 and 5.07%, respectively. The VF rates were 6.18, 11.79, and 13.70% in the LLLV, MLLV, and HLLV groups, respectively (<jats:italic>p<\/jats:italic> &amp;lt;\u202f0.001). The iLLV and pLLV groups had VF rates of 8.82 and 8.14%, respectively (<jats:italic>p<\/jats:italic> =\u202f0.397). Multivariate logistic regression analysis revealed that the gender, ethnicity, age at antiretroviral therapy initiation, baseline CD4<jats:sup>+<\/jats:sup> T lymphocyte count, and current treatment regimen were factors influencing the occurrence of LLV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The incidence of LLV among people living with HIV\/AIDS treated with INSTI-sparing regimens in Guizhou Province is relatively high and is mainly influenced by factors such as age, CD4<jats:sup>+<\/jats:sup> T lymphocyte count and treatment regimens. A comprehensive assessment of these factors is essential to implement targeted interventions that prevent LLV and enhance the effectiveness of antiretroviral therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1535285","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:28:22Z","timestamp":1753853302000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of low-level viremia in people living with HIV\/AIDS and its impact on virological failure in Guizhou Province, China"],"prefix":"10.3389","volume":"13","author":[{"given":"Yan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinling","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenji","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maosi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/s0140-6736(02)11722-3","article-title":"Time to act: global apathy towards HIV\/AIDS is a crime against humanity","volume":"360","author":"Hogg","year":"2002","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4172\/2155-6113.1000565","article-title":"Frequent episodes of detectable viremia in HIV treatment-experienced children is ssociated with a decline in CD4+ T-cells over time","volume":"7","author":"Paintsil","year":"2016","journal-title":"J AIDS Clin Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S1473-3099(17)30680-1","article-title":"Stepping up HIV-1 low-level viraemia surveillance in South Africa","volume":"18","author":"Castagna","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev-med-110918-034551","article-title":"Prevention of HIV transmission and the HPTN 052 study","volume":"71","author":"Cohen","year":"2020","journal-title":"Annu Rev Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3969\/j.issn.1002-1310.2022.01.005","article-title":"Advanced review of influencing factors and clinical significance of Low-level HIV viremia","volume":"44","author":"Li","year":"2022","journal-title":"Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jinf.2010.11.001","article-title":"The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART","volume":"62","author":"Widdrington","year":"2011","journal-title":"J Infect"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/2325957416680028","article-title":"Characterizing patients with very-low-level HIV viremia: a community-based study","volume":"16","author":"Helou","year":"2017","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/hiv.12413","article-title":"Very low level viraemia and risk of virological failure in treated HIV-1-infected patients","volume":"18","author":"Teira","year":"2017","journal-title":"HIV Med"},{"key":"ref11","volume-title":"National free HIV antiviral drug treatment manual","year":"2016"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","article-title":"Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status","volume":"12","author":"Crespo-Bermejo","year":"2021","journal-title":"Virulence"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12879-020-4837-y","article-title":"Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.11847\/zgggws1132975","article-title":"Impact of HIV low-level viraemia on virological failure among HIV\/AIDS people receiving antiretroviral therapy","volume":"38","author":"An","year":"2022","journal-title":"J Pract Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1501961833","DOI":"10.1177\/2325958220979817","article-title":"Low-level viremia predicts virological failure in HIV-infected Omani patients receiving antiretroviral therapy","volume":"19","author":"Gaifer","year":"2020","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e180761","DOI":"10.1371\/journal.pone.0180761","article-title":"Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment","volume":"12","author":"Elvstam","year":"2017","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14787210.2017.1250624","article-title":"Strategies to limit immune-activation in HIV patients","volume":"15","author":"Bandera","year":"2017","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.2147\/IDR.S332924","article-title":"Persistent low-level viremia is an independent risk factor for virologic failure: a retrospective cohort study in China","volume":"14","author":"Li","year":"2021","journal-title":"Infect Drug Resist"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3787\/jbjc202303010079","article-title":"Analysis on the incidence and influencing factors of low-level viraemia among HIV\/AIDS patients in Henan","volume":"38","author":"Ji","year":"2023","journal-title":"Disease Monit"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"19667","DOI":"10.7448\/IAS.17.4.19667","article-title":"Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV cohort study","volume":"17","author":"Leierer","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"ref21","first-page":"908","article-title":"Incidence of low-level viraemia among HIV\/AIDS patients with antiviral therapy in Yunnan province, 2004 \u2013 2018: a retrospective analysis","volume":"7","author":"An","year":"2022","journal-title":"Chin J Public Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e253000","DOI":"10.1371\/journal.pone.0253000","article-title":"Treatment outcomes in HIV infected patients older than 50 years attending an HIV clinic in Harare, Zimbabwe: a cohort study","volume":"16","author":"Shamu","year":"2021","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"800839","DOI":"10.3389\/fpubh.2022.800839","article-title":"Higher risk of mortality and virologic failure in HIV-infected patients with high viral load at antiretroviral therapy initiation: an observational cohort study in Chongqing, China","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Public Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12981-022-00447-2","article-title":"Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana","volume":"19","author":"Opoku","year":"2022","journal-title":"AIDS Res Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/jac\/dkt484","article-title":"Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection","volume":"69","author":"Vancoillie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/01.aids.0000188426.87538.ed","article-title":"Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies\/ml: the impact of highly active antiretroviral therapy","volume":"19","author":"Palmisano","year":"2005","journal-title":"AIDS"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3760\/cma.j.issn.0253-9624.2015.01.004","article-title":"Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013","volume":"49","author":"Yang","year":"2015","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1535285\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T05:28:46Z","timestamp":1753853326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1535285\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":27,"alternative-id":["10.3389\/fpubh.2025.1535285"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1535285","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"1535285"}}